Bullous Pemphigoid

Condition 101

What is the definition of Bullous Pemphigoid?

Bullous pemphigoid is a skin disorder characterized by blisters.

What are the causes for Bullous Pemphigoid?

Bullous pemphigoid is an autoimmune disorder that occurs when the body's immune system attacks and destroys healthy body tissue by mistake. Specifically, the immune system attacks the proteins that attach the top layer of skin (epidermis) to the bottom layer of skin.

This disorder usually occurs in older persons and is rare in young people. Symptoms come and go. The condition often goes away within 5 years.

What are the symptoms for Bullous Pemphigoid?

Most people with this disorder have itchy skin that may be severe. In most cases, there are blisters, called bullae.

  • Blisters are usually located on the arms, legs, or middle of the body. In rare cases, blisters can form in the mouth.
  • The blisters may break open and form open sores (ulcers).

What are the current treatments for Bullous Pemphigoid?

Anti-inflammatory medicines called corticosteroids may be prescribed. They may be taken by mouth or applied to the skin. More powerful medicines may be used to help suppress the immune system if steroids do not work, or to allow lower steroid doses to be used.

Antibiotics in the tetracycline family may be useful. Niacin (a B complex vitamin) is sometimes given along with tetracycline.

Your provider may suggest self-care measures. These may include:

  • Applying anti-itch creams to the skin
  • Using mild soaps and applying moisturizer to the skin after bathing
  • Protecting the affected skin from sun exposure and from injury

What is the outlook (prognosis) for Bullous Pemphigoid?

Bullous pemphigoid usually responds well to treatment. The medicine can often be stopped after several years. The disease sometimes returns after treatment is stopped.

What are the possible complications for Bullous Pemphigoid?

Skin infection is the most common complication.

Complications resulting from treatment may also occur, especially from taking corticosteroids.

When should I contact a medical professional for Bullous Pemphigoid?

Contact your provider if you have:

  • Unexplained blisters on your skin
  • An itchy rash that continues despite home treatment


Habif TP. Vesicular and bullous diseases. In: Habif TP, ed. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th ed. Philadelphia, PA: Elsevier; 2016:chap 16.

PeñaS, Werth VP. Bullous pemphigoid. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson IH, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 5th ed. Philadelphia, PA: Elsevier; 2018:chap 33.

Latest Research

Latest Advance
  • Condition: Psychiatric Comorbidity in Individuals with Bullous Pemphigoid (BP)
  • Journal: BMC psychiatry
  • Treatment Used: Prescribed Medications
  • Number of Patients: 6470450
  • Published —
This study investigated the association between bullous pemphigoid (skin disorder; BP) and all bullous disorders (ABD) with a broad array of psychiatric disorders, exploring the influence of prescribed medications.
Latest Advance
  • Condition: Benign Mucous Membrane Pemphigoid
  • Journal: The Journal of dermatological treatment
  • Treatment Used: Rituximab
  • Number of Patients: 24
  • Published —
This study tested the safety and efficacy of using rituximab to treat patients with benign mucous membrane pemphigoid.
Latest Advance
  • Condition: Type 2 Diabetes Mellitus (T2DM)
  • Journal: Drug safety
  • Treatment Used: Alogliptin
  • Number of Patients: 0
  • Published —
This article preformed a benefit-risk assessment to place alogliptin within the current armamentarium of type 2 diabetes mellitus (T2DM) and aid physicians when choosing optimal diabetes treatment for their patients.
Latest Advance
  • Condition: Bullous Pemphigoid (BP)
  • Journal: International journal of dermatology
  • Treatment Used: Dipeptidyl Peptidase-4 Inhibitors (DPP4i)
  • Number of Patients: 89
  • Published —
This study described the prevalence, socio-demographic, clinical, and histopathological characteristics, and outcome after drug withdrawal in with dipeptidyl peptidase-4 inhibitors (DPP4i)-associated bullous pemphigoid (large blisters; BP).

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 18
  • Start Date: March 11, 2020
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
Clinical Trial
Diagnostic Test
  • Status: Recruiting
  • Study Type: Diagnostic Test
  • Participants: 300
  • Start Date: February 1, 2020
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
Clinical Trial
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 30
  • Start Date: January 30, 2020
Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid